Decker Retirement Planning Inc. Makes New Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Decker Retirement Planning Inc. acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 26,953 shares of the specialty pharmaceutical company's stock, valued at approximately $1,805,000. ANI Pharmaceuticals makes up approximately 1.1% of Decker Retirement Planning Inc.'s portfolio, making the stock its 14th biggest position. Decker Retirement Planning Inc. owned 0.12% of ANI Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. US Bancorp DE grew its position in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares in the last quarter. GAMMA Investing LLC grew its position in ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after acquiring an additional 881 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $166,000. Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $200,000. Finally, Bridgefront Capital LLC bought a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $204,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the sale, the senior vice president now directly owns 89,897 shares in the company, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the sale, the insider now owns 107,317 shares in the company, valued at approximately $6,487,312.65. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,681 shares of company stock worth $346,854. 12.70% of the stock is owned by insiders.

ANI Pharmaceuticals Stock Performance

ANIP traded down $0.31 during trading hours on Friday, hitting $65.50. 325,389 shares of the stock were exchanged, compared to its average volume of 311,463. The stock has a 50-day simple moving average of $64.31 and a 200-day simple moving average of $61.65. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 14.62 and a beta of 0.55. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to analysts' expectations of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The firm's revenue for the quarter was up 43.4% on a year-over-year basis. During the same period last year, the business posted $0.82 earnings per share. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Ratings Changes

ANIP has been the subject of several recent analyst reports. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Guggenheim reiterated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective for the company. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.